Good point Hotrod. The hiring is a proactive approach in the event they go it alone if offers for a successful p3 Product do not satisfy management. I doubt it will come to this but they want to cover potential potholes along the road. It is getting closer and closer. What I’ll be interested is if there’s any deaths among the patients so far. I hope this is asked in the next conference with the CEO. That is the major stumbling block that we have to overcome from the p2 trial. The management is confident that the cause of this is the medical care system in the countries where the trials were conducted and/or the condition of the patients before the trials were conducted. I think they rectified these problems for the p3 trial.
News 
Market Data 
Discover 
